Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/48356
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGauci, Marise-
dc.contributor.authorWirth, Francesca-
dc.contributor.authorCamilleri, Liberato-
dc.contributor.authorAzzopardi, Lilian M.-
dc.contributor.authorSerracino-Inglott, Anthony-
dc.date.accessioned2019-11-06T09:18:55Z-
dc.date.available2019-11-06T09:18:55Z-
dc.date.issued2017-
dc.identifier.citationGauci, M., Wirth, F., Camilleri, L., Azzopardi, L. M., & Serracino-Inglott, A. (2017). Design and application of a medication assessment tool for secondary prevention of stroke. International Journal of Clinical Pharmacy, 39(5), 1008-1012.en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar/handle/123456789/48356-
dc.description.abstractBackground Optimisation of drug therapy is essential in the care of older persons and may be facilitated by application of medication assessment tools (MATs). Objective To design, psychometrically evaluate and apply an innovative MAT for secondary prevention of ischaemic stroke with particular relevance to older persons. Method Review criteria were selected from clinical practice guidelines and MAT-CVA was developed, validated and tested for reliability and feasibility. MAT-CVA was applied to 150 patients with a diagnosis of ischaemic stroke or transient ischaemic attack admitted to a rehabilitation hospital. Results MAT-CVA consists of 17 criteria sectioned into antithrombotic, lipid lowering, antihypertensive and glycaemic therapy. Content validity was demonstrated for all criteria. Reliability was confirmed with kappa values of 0.80 for both inter- and intraobserver agreements. Mean application time for the two observers was 5.55 and 6.56 min. Adherence to applicable criteria was 55% and justified non-adherence was 22.3%. Non-adherence was predominantly evident for prescription of anticoagulation in concurrent atrial fibrillation (36.4%), thiazide diuretics ± angiotensin converting enzyme inhibitors for hypertension (26.8%) and dipyridamole at the recommended dose (24.0%). Conclusion Application of MATCVA indicated good overall adherence and identified gaps in clinical performance which may be targeted to enhance drug therapy optimisation.en_GB
dc.language.isoenen_GB
dc.publisherSpringer Netherlandsen_GB
dc.rightsinfo:eu-repo/semantics/restrictedAccessen_GB
dc.subjectOlder people -- Case studiesen_GB
dc.subjectOlder people -- Careen_GB
dc.subjectIschemiaen_GB
dc.subjectDrugs -- Dosage -- Reductionen_GB
dc.titleDesign and application of a medication assessment tool for secondary prevention of strokeen_GB
dc.typearticleen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holderen_GB
dc.description.reviewedpeer-revieweden_GB
dc.identifier.doi10.1007/s11096-017-0515-6-
dc.publication.titleInternational Journal of Clinical Pharmacyen_GB
Appears in Collections:Scholarly Works - FacM&SPha
Scholarly Works - FacSciSOR

Files in This Item:
File Description SizeFormat 
Design_and_application_of_a_medication_assessment_tool_for_secondary_prevention_of_stroke.pdf
  Restricted Access
238.59 kBAdobe PDFView/Open Request a copy


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.